Galectin-3 and the Development of Heart Failure after Acute Coronary Syndrome: Pilot Experience from PROVE IT-TIMI 22 | Zendy

E. Wilson Grandin | Zendy; Petr Jarolı́m | Zendy; Sabina A. Murphy | Zendy; Lea Ritterova | Zendy; Christopher P. Can | Zendy; Eugene Braunwald | Zendy; David A. Morrow | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Galectin-3 and the Development of Heart Failure after Acute Coronary Syndrome: Pilot Experience from PROVE IT-TIMI 22

Author(s) -

E. Wilson Grandin,

Petr Jarolı́m,

Sabina A. Murphy,

Lea Ritterova,

Christopher P. Can,

Eugene Braunwald,

David A. Morrow

Publication year - 2011

Publication title -

clinical chemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.705

H-Index - 218

eISSN - 1530-8561

pISSN - 0009-9147

DOI - 10.1373/clinchem.2011.174359

Subject(s) - medicine , galectin 3 , heart failure , quartile , acute coronary syndrome , cardiology , timi , odds ratio , natriuretic peptide , confidence interval , myocardial infarction , percutaneous coronary intervention

Galectin-3 is a β-galactoside-binding lectin that has been implicated in cardiac fibrosis and remodeling, is increased in models of failure-prone hearts, and has prognostic value in patients with heart failure (HF). The relationship between galectin-3 and the development of HF after acute coronary syndrome (ACS) is unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research